Addressing gaps in care of people with conditions affecting sex development and maturation


Differences of sex development are conditions with discrepancies between chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal sex development being (almost) unaffected in most patients. To expedite progress in the care of people affected by differences of sex development and congenital hypogonadotropic hypogonadism, the European Union has funded a number of scientific networks. Two Actions of the Cooperation of Science and Technology (COST) programmes — DSDnet (BM1303) and GnRH Network (BM1105) — provided the framework for ground-breaking research and allowed the development of position papers on diagnostic procedures and special laboratory analyses as well as clinical management. Both Actions developed educational programmes to increase expertise and promote interest in this area of science and medicine. In this Perspective article, we discuss the success of the COST Actions DSDnet and GnRH Network and the European Reference Network for Rare Endocrine Conditions (Endo–ERN), and provide recommendations for future research.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Hughes, I. A. et al. Consensus statement on management of intersex disorders. Arch. Dis. Child. 91, 554–563 (2006).

    CAS  Article  Google Scholar 

  2. 2.

    Flück, C. E. et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am. J. Hum. Genet. 89, 201–18 (2011).

    Article  Google Scholar 

  3. 3.

    Croft, B. et al. Human sex reversal is caused by duplication or deletion of core enhancers upstream of SOX9. Nat. Commun. 9, 5319 (2018).

    Article  Google Scholar 

  4. 4.

    Cox, K. et al. Novel associations in disorders of sex development: findings from the I-DSD Registry. J. Clin. Endocrinol. Metab. 99, E348–E355 (2014).

    CAS  Article  Google Scholar 

  5. 5.

    Lucas-Herald, A. et al. The long-term outcome of boys with partial androgen insensitivity syndrome and a mutation in the androgen receptor gene. J. Clin. Endocrinol. Metab. 101, 3959–3967 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Schweizer, K., Brunner, F., Gedrose, B., Handford, C. & Richter-Appelt, H. Coping with diverse sex development: treatment experiences and psychosocial support during childhood and adolescence and adult well-being. J. Pediatr. Psychol. 42, 504–519 (2016).

    Google Scholar 

  7. 7.

    Ahmed, S. F. et al. Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clin. Endocrinol. 84, 771–788 (2016).

    Article  Google Scholar 

  8. 8.

    Boehm, U. et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 11, 547–564 (2015).

    Article  Google Scholar 

  9. 9.

    Bonomi, M. et al. Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). Eur. J. Endocrinol. 178, 23–32 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Cools, M. et al. Caring for individuals with a difference of sex development (DSD): a Consensus Statement. Nat. Rev. Endocrinol. 14, 415–429 (2018).

    Article  Google Scholar 

  11. 11.

    Ahmed, S. F., Khwaja, O. & Hughes, I. A. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. 85, 120–124 (2000).

    CAS  Article  Google Scholar 

  12. 12.

    Dwyer, A. A. et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 98, E1790–1795 (2013).

    CAS  Article  Google Scholar 

  13. 13.

    Dwyer, A. A., Raivio, T. & Pitteloud, N. Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract. Res. Clin. Endocrinol. Metab. 29, 91–103 (2015).

    CAS  Article  Google Scholar 

  14. 14.

    Dwyer, A. A., Quinton, R., Pitteloud, N. & Morin, D. Psychosexual development in men with congenital hypogonadotropic hypogonadism on long-term treatment: a mixed methods study. Sex. Med. 3, 32–41 (2015).

    Article  Google Scholar 

  15. 15.

    Audi, L. et al. Genetics in endocrinology: approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 ‘DSDnet’. Eur. J. Endocrinol. https://doi.org/10.1530/EJE-18-0256 (2018).

    Article  Google Scholar 

  16. 16.

    Cariboni, A. et al. Dysfunctional SEMA3E signalling underlies gonadotropin-releasing hormone neuron deficiency in Kallmann syndrome. J. Clin. Invest. 125, 2413–2428 (2015).

    Article  Google Scholar 

  17. 17.

    Parkash, J. et al. Semaphorin7A regulates neuroglial plasticity in the adult hypothalamic median eminence. Nat. Commun. 6, 6385 (2015).

    CAS  Article  Google Scholar 

  18. 18.

    Miraoui, H. et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am. J. Hum. Genet. 92, 725–743 (2013).

    CAS  Article  Google Scholar 

  19. 19.

    Xu, C. et al. KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. EMBO Mol. Med. 9, 1379–1397 (2017).

    CAS  Article  Google Scholar 

  20. 20.

    Bouilly, J. et al. DCC/NTN1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron development. Hum. Mol. Genet. 27, 359–372 (2018).

    CAS  Article  Google Scholar 

  21. 21.

    Harris, A. et al. ZNRF3 functions in mammalian sex determination by inhibiting canonical WNT signalling. Proc. Natl Acad. Sci. U S A 115, 5474–5479 (2018).

    CAS  Article  Google Scholar 

  22. 22.

    Bashamboo, A. et al. Loss of function of the nuclear receptor NR2F2, encoding COUP-TF2, causes testis development and cardiac defects in 46,XX children. Am. J. Hum. Genet. 102, 487–493 (2018).

    CAS  Article  Google Scholar 

  23. 23.

    Eggers, S. et al. Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort. Genome Biol. 17, 243 (2016).

    Article  Google Scholar 

  24. 24.

    Ridder, J. D. et al. SDgeneMatch, a new tool to aid the identification of the genetic causes of DSD. ESPE Abstracts. 89, P-P1-216 (2018).

    Google Scholar 

  25. 25.

    Kulle, A. et al. Steroid hormone analysis in diagnosis and treatment of DSD: position paper of EU COST Action BM 1303 ‘DSDnet’. Eur. J. Endocrinol. 176, P1–P9 (2017).

    CAS  Article  Google Scholar 

  26. 26.

    Segal, T. Y., Mehta, A., Anazodo, A., Hindmarsh, P. C. & Dattani, M. T. Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J. Clin. Endocrinol. Metab. 94, 780–785 (2009).

    CAS  Article  Google Scholar 

  27. 27.

    Trabado, S. et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-centre study of 281 patients. J. Clin. Endocrinol. Metab. 99, E268–275 (2014).

    CAS  Article  Google Scholar 

  28. 28.

    Greaves, R. F. et al. Current state and recommendations for harmonization of serum/plasma 17-hydroxyprogesterone mass spectrometry methods. Clin. Chem. Lab. Med. 56, 1685–1697 (2018).

    CAS  Article  Google Scholar 

  29. 29.

    Cools, M. et al. Response to the Council of Europe Human Rights Commissioner’s Issue Paper on Human Rights and Intersex People. Eur. Urol. 70, 407–409 (2016).

    Article  Google Scholar 

  30. 30.

    Bertalan, R. et al. Evaluation of DSD training schools organized by cost action BM1303 ‘DSDnet’. Orphanet J. Rare Dis. 13, 227 (2018).

    CAS  Article  Google Scholar 

  31. 31.

    Kyriakou, A. et al. Current models of care for disorders of sex development - results from an international survey of specialist centres. Orphanet J. Rare Dis. 11, 155 (2016).

    Article  Google Scholar 

  32. 32.

    Dessens, A. et al. Understanding the needs of professionals who provide psychosocial care for children and adults with disorders of sex development. BMJ Paediatr. Open 1, e000132 (2017).

    Article  Google Scholar 

  33. 33.

    Minto, C. L., Liao, L. M., Woodhouse, C. R., Ransley, P. G. & Creighton, S. M. The effect of clitoral surgery on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a cross-sectional study. Lancet 361, 1252–1257 (2003).

    Article  Google Scholar 

  34. 34.

    Frisen, L. et al. Gender role behaviour, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J. Clin. Endocrinol. Metab. 94, 3432–3439 (2009).

    CAS  Article  Google Scholar 

  35. 35.

    van der Zwan, Y. G. et al. Severity of virilization is associated with cosmetic appearance and sexual function in women with congenital adrenal hyperplasia: a cross-sectional study. J. Sex. Med. 10, 866–875 (2013).

    Article  Google Scholar 

  36. 36.

    Callens, N. et al. Recalled and current gender role behaviour, gender identity and sexual orientation in adults with disorders/differences of sex development. Horm. Behav. 86, 8–20 (2016).

    Article  Google Scholar 

  37. 37.

    Sanders, C. et al. Involving individuals with disorders of sex development and their parents in exploring new models of shared learning: proceedings from a DSDnet COST Action Workshop. Sex. Dev. https://doi.org/10.1159/000490081 (2018).

  38. 38.

    Dwyer, A. A., Quinton, R., Morin, D. & Pitteloud, N. Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for online interventions and peer-to-peer support. Orphanet J. Rare Dis. 9, 83 (2014).

    Article  Google Scholar 

  39. 39.

    COST Action BM1105, Badiu, C. et al. Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet J. Rare Dis. 12, 57 (2017).

    Article  Google Scholar 

  40. 40.

    Ali, S. R. et al. The current landscape of European registries for rare endocrine conditions. Eur. J. Endocrinol. 180, 89–98 (2019).

    CAS  Article  Google Scholar 

  41. 41.

    Bick, D., Jones, M., Taylor, S. L., Taft, R. J., Belmont, J. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J. Med. Genet. https://doi.org/10.1136/jmedgenet-2019-106111(2019).

  42. 42.

    Carre, G. A. & Greenfield, A. Characterizing novel pathways in testis determination using mouse genetics. Sex. Dev. 8, 199–207 (2014).

    CAS  Article  Google Scholar 

  43. 43.

    Carré, G. A. et al. Loss of p300 and CBP disrupts histone acetylation at the mouse Sry promoter and causes XY gonadal sex reversal. Hum. Mol. Genet. 27, 190–198 (2017).

    Article  Google Scholar 

  44. 44.

    Greenfield, A. Editing mammalian genomes: ethical perspectives. Mamm. Genome 28, 388–393 (2017).

    CAS  Article  Google Scholar 

  45. 45.

    Warr, N. et al. Transgenic overexpression of Map3k4 rescues T-associated sex reversal (Tas) in mice. Hum. Mol. Genet. 23, 3035–3044 (2014).

    CAS  Article  Google Scholar 

  46. 46.

    Cassatella, D. et al. Congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty have distinct genetic architectures. Eur. J. Endocrinol. 178, 377–388 (2018).

    CAS  Article  Google Scholar 

Download references


The authors thank all members and participants of both COST Actions for their continuous support and active input.

Author information





The authors contributed equally to all aspects of the article.

Corresponding author

Correspondence to Olaf Hiort.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information

Nature Reviews Endocrinology thanks C. H. Gravholt and the other, anonymous, reviewers for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

CHUV: www.chuv.ch/en/hhn/hhn-home/

COST Action DSDnet: www.dsdnet.eu

DSD-Life: https://www.dsd-life.eu/

DSDnet: www.dsdnet.eu

Endo–ERN: https://endo-ern.eu/

European Commission European Reference Networks: https://ec.europa.eu/health/ern_en

GnRH Network: www.gnrhnetwork.eu

I-CAH Registry: www.i-cah.org

I-DSD Registry: www.i-dsd.org

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hiort, O., Cools, M., Springer, A. et al. Addressing gaps in care of people with conditions affecting sex development and maturation. Nat Rev Endocrinol 15, 615–622 (2019). https://doi.org/10.1038/s41574-019-0238-y

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing